Abstract
BB-K8, an aminoglycoside antibiotic which is a derivative of kanamycin, was tested in vitro against 466 clinical bacterial isolates. Over 90% of gram-negative bacilli, except Proteus spp., were inhibited by 3.12 mug of BB-K8 per ml. This antibiotic was consistently more active than kanamycin but less active than tobramycin or gentamicin. Unlike kanamycin, BB-K8 was active against Pseudomonas aeruginosa. Eleven of 19 isolates resistant to either gentamicin or tobramycin, or both, were susceptible to BB-K8.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
